2023 World Conference on Lung Cancer (Posters)-EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC

EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the feasibility and efficacy of adding amivantamab as a salvage strategy in patients with metastatic non-small cell lung cancer (NSCLC) who had previously received EGFR targeted therapy. The study included 13 patients who received amivantamab after progression on EGFR TKI treatment. Of the patients, 8 had common EGFR mutations and 5 had EGFR exon 20 mutations. The objective response rate (ORR) was 75% in the group with common EGFR mutations and 100% in the group with EGFR exon 20 mutations. The median duration of therapy was 2.3 months in the common EGFR mutation group and 5.5 months in the EGFR exon 20 mutation group. The median progression-free survival was 4.7 months in both groups. The safety profile of amivantamab included grade 3 toxicities such as nausea, diarrhea, and skin rash. 16% of the patients experienced grade 3 infusion reactions. The study concluded that incorporating amivantamab into prior EGFR targeted therapy appears to be a feasible option, although osimertinib was found to be the most well-tolerated and effective TKI. Further studies are needed to identify patient subgroups and confirm these findings through prospective analysis. Overall, amivantamab shows promise as a salvage therapy for patients with metastatic NSCLC who have progressed on previous EGFR TKI treatment.

Asset Subtitle

Nir Peled

Meta Tag

Speaker Nir Peled

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

amivantamab

salvage strategy

metastatic non-small cell lung cancer

EGFR targeted therapy

EGFR TKI treatment

common EGFR mutations

EGFR exon 20 mutations

objective response rate

duration of therapy

progression-free survival